ARS-1323 is primarily utilized in the field of medical research, particularly in the study of cancer therapeutics. It functions as a selective inhibitor targeting KRAS protein mutations, especially the G12C variant, which is a key driver in tumor growth and proliferation in cancers such as non-small cell lung cancer. Researchers employ ARS-1323 to investigate its potential in disrupting aberrant KRAS signaling in cancer cells, which could lead to the development of novel anti-cancer drugs. Its application extends to preclinical studies, where it is used to assess efficacy, safety, and mechanisms of action in various cancer models. Additionally, ARS-1323 is explored for its role in combination therapies, aiming to enhance the effectiveness of existing treatments and reduce potential side effects. Its targeted approach makes it a valuable tool in advancing precision medicine for oncology, with ongoing research evaluating its potential for clinical translation.